Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients

Trial Profile

Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms METREX
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Nov 2017 According to a GlaxoSmithKline media release, based on the data from METREX and METREO studies the company has submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA), seeking approval of mepolizumab as an add-on to maintenance treatment for patients who have chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. Regulatory filings in other countries are planned during the course of 2017 and 2018.
    • 12 Sep 2017 According to a GlaxoSmithKline media release, results of the METREX and METREO studies, along with data from a pre-specified meta-analysis combining both studies, have been published in the New England Journal of Medicine (NEJM), with simultaneous presentation at the European Respiratory Society (ERS) International Congress 2017.
    • 12 Sep 2017 Results published in GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top